Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Up 23.7% in January

Iterum Therapeutics PLC (NASDAQ:ITRM) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 1,960,331 shares, a growth of 23.7% from the January 15th total of 1,584,707 shares. Approximately 3.8% of the shares of the company are short sold. Based on an average daily trading volume, of 365,626 shares, the days-to-cover ratio is presently 5.4 days. Based on an average daily trading volume, of 365,626 shares, the days-to-cover ratio is presently 5.4 days. Approximately 3.8% of the shares of the company are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alchemi Wealth LLC purchased a new stake in shares of Iterum Therapeutics during the 4th quarter worth about $90,000. Jane Street Group LLC raised its holdings in Iterum Therapeutics by 1,893.5% in the 4th quarter. Jane Street Group LLC now owns 289,410 shares of the company’s stock worth $97,000 after purchasing an additional 274,892 shares during the period. Virtu Financial LLC purchased a new position in Iterum Therapeutics during the third quarter worth approximately $32,000. Apollon Financial LLC boosted its position in Iterum Therapeutics by 151.8% during the fourth quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after purchasing an additional 380,000 shares in the last quarter. Finally, OneDigital Investment Advisors LLC grew its holdings in Iterum Therapeutics by 18.6% in the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after purchasing an additional 30,000 shares during the period. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Iterum Therapeutics in a report on Monday, December 22nd. Wall Street Zen lowered Iterum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.00.

Iterum Therapeutics Stock Down 6.8%

Iterum Therapeutics stock opened at $0.26 on Wednesday. Iterum Therapeutics has a 52 week low of $0.25 and a 52 week high of $1.56. The firm has a market cap of $13.65 million, a price-to-earnings ratio of -0.34 and a beta of 2.97. The business’s 50-day moving average price is $0.34 and its 200 day moving average price is $0.54.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).